Chapter 61. Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia

  1. Frederick R. Appelbaum MD Member Director Professor Head2,3,
  2. Stephen J. Forman MD Director Staff Physician4,5,
  3. Robert S. Negrin MD Professor of Medicine Chief6 and
  4. Karl G. Blume MD, FACP Emeritus Professor of Medicine6,7
  1. David B. Miklos MD, PhD Assistant Professor of Medicine

Published Online: 5 MAR 2009

DOI: 10.1002/9781444303537.ch61

Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation, Fourth Edition

Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation, Fourth Edition

How to Cite

Miklos, D. B. (2009) Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia, in Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation, Fourth Edition (eds F. R. Appelbaum, S. J. Forman, R. S. Negrin and K. G. Blume), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444303537.ch61

Editor Information

  1. 2

    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA

  2. 3

    Division of Medical Oncology, University of Washington School of Medicine, Seattle, Washington, USA

  3. 4

    Department of Hematology and Hematopoietic Cell Transplantation, Duarte, California, USA

  4. 5

    Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA

  5. 6

    Division of Blood and Marrow Transplantation, Stanford University, Stanford, California, USA

  6. 7

    Division of Bone Marrow Transplantation, Department of Medicine, Stanford University, School of Medicine, Stanford, California, USA

Author Information

  1. Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University, Stanford, California, USA

Publication History

  1. Published Online: 5 MAR 2009
  2. Published Print: 27 FEB 2009

ISBN Information

Print ISBN: 9781405153485

Online ISBN: 9781444303537

SEARCH

Keywords:

  • hematopoietic cell transplantation for chronic lymphocytic leukemia;
  • prognosistic markers;
  • markers of CLL tumor burden;
  • cytogenetic prognostic markers;
  • methods for detecting MRD in CLL patients;
  • autologous HCT;
  • relapses and refractory disease

Summary

This chapter contains sections titled:

  • Introduction

  • Incidence and etiology of CLL

  • Clinical presentation, diagnosis, and staging

  • Prognosistic markers

  • Response criteria

  • Methods for detecting MRD in CLL patients

  • CLL therapy

  • Autologous HCT

  • Ex vivo monoclonal antibody purging of autologous grafts

  • Allogeneic HCT using high-dose conditioning regimens

  • HCT recommendations for CLL

  • References